Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Prevention of AKI in Post-CABG T2DM
NCT04523064Phase 4Completed
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in acute kidney injury (AKI), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Started Sep 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04523064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523064.